Cargando…
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
INTRODUCTION: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. METHODS: An exploratory analysis of a prospective, multi-institutional coh...
Autores principales: | Yoshimura, Katsuhiro, Inoue, Yusuke, Inui, Naoki, Karayama, Masato, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Sugimura, Haruhiko, Suda, Takafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569583/ https://www.ncbi.nlm.nih.gov/pubmed/34766065 http://dx.doi.org/10.1016/j.jtocrr.2021.100239 |
Ejemplares similares
-
Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non–Small Cell Lung Cancer After Nivolumab Therapy
por: Karayama, Masato, et al.
Publicado: (2022) -
Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis
por: Suzuki, Yuzo, et al.
Publicado: (2018) -
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017) -
Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia
por: Kazuo, Tsuchiya, et al.
Publicado: (2019) -
Author Correction: Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia
por: Tsuchiya, Kazuo, et al.
Publicado: (2020)